Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 7/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349891 | 1.00 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL26691320 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL28784343 | 0.81 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2RAB9AACE | |
| SCHEMBL443176 | 0.81 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL443175 | 0.81 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL202763 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL202764 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL30353922 | 0.79 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| Hydrochloric Acid SCHEMBL3924876 | 0.79 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL31205705 | 0.78 | RAB9A (0.41) | ALDH1A1SMN1; SMN2RAB9AACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110249050-B | Library of non-tag encoded compounds | 南纳治疗有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7648978-B2 | Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone | ANGION BIOMEDICA CORP. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1799651-A2 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | Angion Biomedica Corp. (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060116365-A1 | Small molecule modulators of cytokine activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-01 | — | — | US | disclosed |
| WO-2006036981-A2 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | HGF, IL2, IL2RA | ALDH1A1 978/4885SMN1; SMN2 2194/4885RAB9A 928/4885 |
| US-20060116365-A1 | Small molecule modulators of cytokine activity | HGF, IL2, IL2RA | ALDH1A1 978/4885SMN1; SMN2 2194/4885RAB9A 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.